Drug intelligence / Profile preview

methoxyamine + temozolomide

Development stage: Unknown
Lead developer: TRACON Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

Methoxyamine + temozolomide is a combination therapy that works by enhancing the effectiveness of temozolomide through inhibition of base excision repair mechanisms. Temozolomide is an alkylating agent that generates DNA adducts, while methoxyamine (TRC102) binds to apurinic and apyrimidinic sites after removal of N3-methyladenine and N7-methylguanine, inhibiting site recognition of AP endonuclease. This combination has shown activity in various solid tumors including non-small cell lung cancer, granulosa cell ovarian cancer, and colon cancer.

Other names: methoxyamine HCl + temozolomide

Targets

Genomic DNA basesAP site (Apurinic/apyrimidinic site)

Beyond the preview

Go deeper on methoxyamine + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methoxyamine + temozolomide.

Explore the full profile